Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | USP4 | Q13107 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | HRAS | P01112 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | TOP1 | P11387 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19636845 | 0.92 | ERBB2 (0.40) | NAMPTHDAC1HDAC6DRD2MAPK14 | |
| SCHEMBL30944532 | 0.91 | NAMPT (0.42) | NAMPTDRD2MAPK14MAPTCYP17A1 | |
| SCHEMBL30944502 | 0.91 | NAMPT (0.42) | NAMPTDRD2MAPK14MAPTCYP17A1 | |
| SCHEMBL19636934 | 0.91 | ERBB2 (0.41) | NAMPTHDAC1HDAC6DRD2MAPK14 | |
| SCHEMBL30944533 | 0.86 | CYP17A1 (0.41) | NAMPTHDAC1HDAC6DRD2MAPK14 | |
| SCHEMBL25855374 | 0.85 | ERBB2 (0.38) | NAMPTHDAC1HDAC6DRD2MAPK14 | |
| SCHEMBL19633222 | 0.84 | USP4 (0.39) | USP4USP7L3MBTL1KDM4E | |
| SCHEMBL19633220 | 0.83 | ERBB2 (0.40) | HDAC1MAPTUSP4USP7HRAS | |
| SCHEMBL19636936 | 0.82 | ERBB2 (0.40) | HDAC1MAPTUSP4USP7HRAS | |
| SCHEMBL28865597 | 0.82 | NR1H4 (0.47) | NAMPTHDAC1HDAC6USP4USP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458069-B1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | MERSANA THERAPEUTICS, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2019-03-07 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | MERSANA THERAPEUTICS, INC. | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333442-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | NAMPT 3033/4885HDAC1 1672/4885HDAC6 38/4885 |
| US-20190070194-A1 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF | CD79B, CLTB, FCGR3B | NAMPT 3033/4885HDAC1 1672/4885HDAC6 38/4885 |
| US-10660901-B2 | Pyrrolobenzodiazepines and conjugates thereof | CD79B, CLTB, FCGR3B | NAMPT 3033/4885HDAC1 1672/4885HDAC6 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.